ProfileGDS5678 / 1450678_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 94% 95% 94% 97% 95% 95% 95% 95% 95% 92% 94% 94% 94% 93% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.1820394
GSM967853U87-EV human glioblastoma xenograft - Control 28.3998195
GSM967854U87-EV human glioblastoma xenograft - Control 38.0741894
GSM967855U87-EV human glioblastoma xenograft - Control 49.6840297
GSM967856U87-EV human glioblastoma xenograft - Control 58.5882895
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.4065295
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.2585795
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.5256195
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.2634595
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.6687392
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.9868194
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.1613194
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.0730194
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.8326593